<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Heart transplantation: Hyperlipidemia after transplantation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Heart transplantation: Hyperlipidemia after transplantation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Heart transplantation: Hyperlipidemia after transplantation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Howard J Eisen, MD, FACC, FAHA, FHFSA, FAST
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Rosenson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sallie Johnson, PharmD, BCPS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sharon A Hunt, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mason W Freeman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 11, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         After heart transplantation, lipid abnormalities are common, and statin treatment is an important component of heart transplantation therapy. This topic discusses our approach to the management of dyslipidemia and statin therapy, which is characterized by the need to deliver effective lipid therapy despite the presence of interactions between immunosuppressive drugs and lipid lowering therapies.
        </p>
        <p>
         Details on the management of graft vasculopathy are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3524.html" rel="external">
          "Heart Transplantation: Prevention and treatment of cardiac allograft vasculopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3522.html" rel="external">
          "Heart transplantation: Clinical manifestations, diagnosis, and prognosis of cardiac allograft vasculopathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3663729104">
         <span class="h1">
          CAUSES OF HYPERLIPIDEMIA AFTER TRANSPLANTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         After heart transplantation, the risk of hyperlipidemia is increased by factors that include:
        </p>
        <p class="headingAnchor" id="H2437934578">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids may increase lipid levels by causing peripheral insulin resistance, increased hepatic synthesis of very low-density lipoprotein particles, and weight gain. Several studies have documented the association between higher glucocorticoid dose and longer exposure to glucocorticoids and an increased risk of hyperlipidemia [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         One study compared 117 cardiac transplant recipients, 56 percent of whom were maintained on glucocorticoid-free immunosuppression [
         <a href="#rid3">
          3
         </a>
         ]. In patients who did not receive long-term treatment with glucocorticoids, the mean serum cholesterol concentration during follow-up was 21 to 26 percent lower than in those who continued glucocorticoid therapy (205 versus 267 mg/dL [5.3 versus 6.9 mmol/L]). (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids", section on 'Cardiovascular effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2760241950">
         <span class="h2">
          Tacrolimus
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          Tacrolimus
         </a>
         may cause some degree of hyperlipidemia, but data suggest that its effect on lipid profiles is less than that of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         . In a trial of patients treated with cyclosporine who had hyperlipidemia, patients who were randomly changed from cyclosporine to tacrolimus had a greater decrease in total cholesterol (mostly low-density lipoprotein-cholesterol [LDL-C]) than patients who continued on cyclosporine (212 to 186 versus 217 to 209 mg/dL) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1506017306">
         <span class="h2">
          Everolimus and sirolimus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mechanistic target of rapamycin (mTOR) inhibitors increase serum triglycerides, and to a lesser extent, serum LDL-C fractions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a clinical trial of
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         versus
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         in heart transplant recipients, triglyceride levels were increased in patients receiving everolimus compared with those receiving azathioprine (mean triglyceride level at 12 months 3.0 versus 2.0 mmol/L in the azathioprine group) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a clinical trial of
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         versus
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil, hyperlipidemia was more common in patients taking everolimus (12-month prevalence of hyperlipidemia 30 versus 22 percent; relative risk [RR] 1.3, 95% CI 1.0-1.8) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertriglyceridemia as a consequence of mTOR inhibitor use has also been observed in renal transplant recipients. A qualitative review found that mTOR inhibitor use was associated with higher triglyceride and cholesterol levels in 16 of 17 clinical trials [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2852971965">
         <span class="h2">
          Cyclosporine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         interferes with binding of LDL to the LDL receptor [
         <a href="#rid8">
          8
         </a>
         ], and hyperlipidemia occurs in 60 to 83 percent of patients with heart transplantation who take cyclosporine [
         <a href="#rid1">
          1,9-13
         </a>
         ]. Lipid abnormalities associated with cyclosporine include elevations in the serum levels of total cholesterol, LDL-C, and serum triglycerides [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         The magnitude of these elevations was illustrated in a study of 100 heart transplantation recipients who survived more than three months after surgery [
         <a href="#rid9">
          9
         </a>
         ]. The following differences were noted between the baseline and three-month lipid values:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total cholesterol increased from 168 to 234 mg/dL (4.4 to 6.1 mmol/L)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LDL-C increased from 111 to 148 mg/dL (2.9 to 3.8 mmol/L)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High-density lipoprotein cholesterol (HDL-C) increased from 34 to 47 mg/dL (0.9 to 1.2 mmol/L)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Triglycerides increased from 107 to 195 mg/dL (1.2 to 2.2 mmol/L)
        </p>
        <p>
        </p>
        <p>
         Similar changes in lipid values were seen in patients with heart transplantation who were enrolled in the placebo arm of randomized trials of statin therapy [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3046163646">
         <span class="h2">
          Other factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         era, hyperlipidemia after transplantation was associated with pretransplantation lipid levels, history of coronary artery disease, glucose levels, change in weight, and body mass index [
         <a href="#rid13">
          13,16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3741880955">
         <span class="h1">
          TREATMENT OF HYPERCHOLESTEROLEMIA
         </span>
        </p>
        <p class="headingAnchor" id="H2471080476">
         <span class="h2">
          General measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with hypercholesterolemia after transplantation should be counseled to engage in activities that may help to reduce hypercholesterolemia, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exercise (see
         <a class="medical medical_review" href="/z/d/html/3527.html" rel="external">
          "Heart transplantation in adults: Exercise-based rehabilitation for transplant recipients"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diet (see
         <a class="medical medical_review" href="/z/d/html/4561.html" rel="external">
          "Lipid management with diet or dietary supplements", section on 'Our approach'
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glycemic control (see
         <a class="medical medical_review" href="/z/d/html/7327.html" rel="external">
          "Kidney transplantation in adults: Posttransplantation diabetes mellitus"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1340577291">
         <span class="h2">
          Empiric therapy with a statin
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients who have undergone heart transplantation regardless of lipid levels or prior treatment with a statin, we recommend initial treatment with
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         or
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         rather than treatment with other cholesterol-reducing agents or no therapy (
         <a class="graphic graphic_algorithm graphicRef139419" href="/z/d/graphic/139419.html" rel="external">
          algorithm 1
         </a>
         ). We generally prefer pravastatin to rosuvastatin due to the long experience with pravastatin in heart transplantation.
        </p>
        <p>
         Prior to discharge from heart transplantation surgery, we start therapy with a low dose of either drug (eg,
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         20 mg daily,
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         10 mg daily) and increase the dose to the maximally tolerated dose (ie, pravastatin 40 mg daily, rosuvastatin 20 mg daily) while monitoring liver function tests and creatinine kinase with each dose increase. The typical goal of therapy is to increase to the maximally tolerated dose within four to eight weeks of transplantation. Statin therapy is continued indefinitely.
        </p>
        <p>
         This approach assumes there are no interactions with
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         or
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         ; we do not typically use statins that are metabolized by the CYP3A4 system (eg,
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">
          lovastatin
         </a>
         ) for the initial therapy of hypercholesterolemia due to the potential for interactions. In patients who cannot take a statin, therapy is based on cardiovascular disease (CVD) risk, as described elsewhere in this topic. (See
         <a class="local">
          'Additional therapy based on risk'
         </a>
         below.)
        </p>
        <p>
         For patients with heart transplantation who are intolerant of statins, we typically treat with
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         monotherapy or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. (See
         <a class="local">
          'Additional therapy based on risk'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale
         </strong>
         – This approach is motivated by trial evidence that demonstrates the benefit of statin therapy after transplant and the low incidence of drug-drug interactions with
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         and
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         . The empiric use of a statin after transplantation is consistent with professional guidelines, though our approach differs from the guidelines in that we favor initial and continued use of either pravastatin or rosuvastatin, which have fewer drug-drug interactions than other statins [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mortality risk reduction
         </strong>
         – Evidence from trials that predominantly included patients treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         established the benefit of statin therapy after cardiac transplantation. Though there are no trials of statin therapy among patients primarily treated with
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         , or
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         , the high risk of hypercholesterolemia after heart transplantation and the mortality reduction associated with statin use favors the use of statins in patients taking non-cyclosporine-based regimens. (See
         <a class="local">
          'Causes of hyperlipidemia after transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a small, open-label trial, 97 heart transplant recipients were randomly assigned to
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         20 mg daily or no statin one to two weeks after transplantation [
         <a href="#rid14">
          14
         </a>
         ]. If tolerated, the dose of pravastatin was increased to 40 mg daily at one month. At one year, pravastatin therapy was associated with a higher survival rate (94 versus 78 percent) and a lower risk of cardiac rejection episodes with hemodynamic compromise (6 versus 28 percent). The lower risk of rejection suggested the possibility of an immunosuppressant effect of statins in transplant recipients, though lower rejection rates were not found in later trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In another study, 72 patients were randomized to receive either
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         or usual care [
         <a href="#rid15">
          15
         </a>
         ]. Patients assigned to simvastatin had higher four-year survival (89 versus 70 percent) and a lower incidence of "graft vessel disease" as assessed by intracoronary ultrasound (17 versus 42 percent). In this trial, the rate of allograft rejection was nonsignificantly lower in the simvastatin group (3 versus 14 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a trial that compared the effect of
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         10 mg daily with
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         20 mg daily, the rates of allograft rejection were similar between the two groups [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Choice of statin
         </strong>
         – We favor the use of
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         or
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         due to the lower risk of drug-drug interactions with the commonly used immunosuppressants
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         , and
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         . We typically use pravastatin as the initial statin given the long experience with its use in heart transplantation. While some agents may be compatible (eg,
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         are compatible), many statins and immunosuppressants are incompatible. If one agent in a compatible immunosuppression and statin regimen is changed without knowledge of these interactions to an incompatible combination, hepatotoxicity, rhabdomyolysis, or toxicity of the immunosuppressant (eg, sirolimus) can occur. (See
         <a class="local">
          'Immunosuppression and antihyperlipidemic drug interactions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Effect on cardiac allograft vasculopathy
         </strong>
         – The effect of statins on coronary allograft vasculopathy is described elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3524.html" rel="external">
          "Heart Transplantation: Prevention and treatment of cardiac allograft vasculopathy", section on 'Statins'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Therapy for patients intolerant of statins
         </strong>
         – In patients who cannot takes statins, the motivation for treatment with either
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         or a PCSK9 inhibitor is to gain the benefit of LDL-C reduction. However, it is unclear whether ezetimibe or PCSK9 inhibitors have the same effect on mortality reduction that statins have; there have been no prospective studies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3752678961">
         <span class="h2">
          Additional therapy based on risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         After the maximum dose of
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         or
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         is established, management of hypercholesterolemia is based on the presence of CVD risk factors and LDL-C levels (
         <a class="graphic graphic_algorithm graphicRef139419" href="/z/d/graphic/139419.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choosing LDL-C treatment goals
         </strong>
         –
         <strong>
         </strong>
         For patients with risk factors for atherosclerotic CVD, such as diabetes (preexisting or acquired posttransplantation), or for those with a prior history of atherosclerotic CVD, such as coronary artery disease, stroke, or peripheral arterial disease, we use the LDL-C goals ideal for the treatment of those disorders. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients without prior atherosclerotic CVD or atherosclerotic CVD risk factors, we treat with the maximally tolerated statin dose rather than to a specific LDL-C goal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients not at goal
         </strong>
         – In patients whose LDL-C level is not suppressed below their target values after initial therapy with a statin, we switch to
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         if the patient is not already taking rosuvastatin (
         <a class="graphic graphic_algorithm graphicRef139419" href="/z/d/graphic/139419.html" rel="external">
          algorithm 1
         </a>
         ). If the patient has not achieved an LDL-C level consistent with appropriate treatment goals with optimal statin therapy, we suggest treating with the addition of either
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         or a PCSK9 inhibitors rather than no therapy or additional therapy with other agents. If agents are added to existing statin therapy, we increase the frequency of immunosuppression levels and liver function test monitoring to assess for possible interactions [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients at goal
         </strong>
         –
         <strong>
         </strong>
         If the LDL-C and triglycerides are at an appropriate level for the patient’s CVD risk factor profile or pancreatitis risk, respectively, we continue the maximally tolerated statin dose and monitor for liver toxicity and rhabdomyolysis as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale
         </strong>
         –
         <strong>
         </strong>
         There are no high-quality studies of specific LDL-C targets in patients who have undergone heart transplantation. In patients with heart transplantation who have secondary prevention indications, the potential benefits of treating to target LDL-C goals (eg, stroke reduction) are extrapolated from the results of trials that included patients with similar secondary prevention indications but who did not have heart transplantation. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of hypertriglyceridemia treatment after heart transplantation has not been specifically studied, but the reduction in pancreatitis risk in patients with a heart transplant is likely similar to its efficacy in persons in the general population. (See
         <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">
          "Hypertriglyceridemia in adults: Management", section on 'Treatment goals'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical experience and the available evidence suggest that these agents have a similar effect on reducing lipid or triglyceride levels and are safe in patients with heart transplantation. The evidence for specific agents for additional hypercholesterolemia therapy include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ezetimibe
         </strong>
         –
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          Ezetimibe
         </a>
         is considered safe in patients with heart transplantation who take
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         , or
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         , though few data are available [
         <a href="#rid19">
          19,20
         </a>
         ]. Small studies suggest ezetimibe reduces LDL-C and does not interfere with immunosuppression when used as additive therapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a study of 34 patients with heart transplantation who had "statin inefficacy" (78 percent) or statin intolerance, treatment with
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         reduced LDL-C levels (137±47 to 89±29 mg/dL) without the need for changes in immunosuppression dose. There was one case of hand edema and one case of rhabdomyolysis in a patient who had multiple prior episodes of rhabdomyolysis attributed to statin use [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a study of 19 transplant recipients who had suboptimal control of LDL cholesterol (baseline LDL-C 171±69 mg/dL) with a statin, the addition of
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         resulted in a decrease in LDL-C (LDL-C at follow-up 109±41 mg/dL). The authors did not report the effects on immunosuppression levels [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          PCSK9 inhibitors
         </strong>
         – In patients without heart transplantation, PCSK9 inhibitors are used to treat patients who do not meet their LDL-C goals after treatment with high-dose statin therapy. The efficacy of PCSK9 inhibitors in patients who have undergone heart transplantation has not been well studied [
         <a href="#rid23">
          23
         </a>
         ], though small studies suggest these agents may be safe in heart transplant recipients:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a meta-analysis of six studies that included 97 patients with heart transplantation treated with PCSK9 inhibitors, LDL-C decreased by 83 mg/dL (95% CI 47-119 mg/dL). There were no serious drug reactions or interactions with calcineurin inhibitors reported [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a study of 65 patients with heart transplantation who received a PCSK9 inhibitor (
         <a class="drug drug_general" data-topicid="103780" href="/z/d/drug information/103780.html" rel="external">
          evolocumab
         </a>
         or
         <a class="drug drug_general" data-topicid="103073" href="/z/d/drug information/103073.html" rel="external">
          alirocumab
         </a>
         ) and who were treated for a median of 1.6 years, median LDL-C decreased from 130 mg/dL (interquartile range [IQR] 102-148 mg/dL) to 55 mg/dL (IQR 35-74 mg/dL), which resulted in an LDL-C of &lt;70 mg/dL in 72 percent of patients [
         <a href="#rid25">
          25
         </a>
         ]. In 33 patients with serial coronary angiography and intravascular ultrasound, coronary plaque thickness and lumen area did not change.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2439707130">
         <span class="h1">
          TREATMENT OF HYPERTRIGLYCERIDEMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of triglyceride treatment in patients with a heart transplant is the same as the goal in the general population, which is to reduce the risk of pancreatitis. The indications for initiating treatment and approach to monitoring treatment are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">
          "Hypertriglyceridemia in adults: Management", section on 'Treatment goals'
         </a>
         .)
        </p>
        <p>
         In patients who already engage in lifestyle modifications and who are maximally treated with
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         but whose triglycerides remain above goal, we typically treat with omega-3 fatty acids; we avoid use of fibrates in this population due to the potential for drug-drug interactions and myotoxicity caused by concomitant renal dysfunction. (See
         <a class="local">
          'Immunosuppression and antihyperlipidemic drug interactions'
         </a>
         below.)
        </p>
        <p>
         Omega-3 fatty acids are not a first-line therapy for the treatment of hypercholesterolemia in patients who have undergone heart transplantation, and their use is limited to the prevention of pancreatitis in patients with hypertriglyceridemia. The safety and efficacy data in this population are limited. One small study included patients with heart transplantation who were treated with either
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         or
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         and who were hypertriglyceridemic. Treatment with omega-3 fatty acid (ie, 4 g daily) decreased triglyceride levels by 20 percent, and therapy was well tolerated (eg, no adverse events, no patient discontinued statin therapy, there were no changes in immunosuppressive therapy) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2110544677">
         <span class="h1">
          IMMUNOSUPPRESSION AND ANTIHYPERLIPIDEMIC DRUG INTERACTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1325868127">
         <span class="h2">
          Fibrates
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not use fibrates in patients who have undergone heart transplantation due to the potential interactions between immunosuppressants and these agents. The studies that describe such interactions have conflicting results and were limited to patients with kidney transplantation who were treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H490766031">
         <span class="h2">
          Statins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many of the statins interact with transplant immunosuppressants. The interactions between specific statin and immunosuppressant combinations are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tacrolimus
         </strong>
         – Interactions between
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         and statins may be less common than interactions between statins and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         , or
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         [
         <a href="#rid29">
          29-31
         </a>
         ]. However, tacrolimus is metabolized by the cytochrome P450 (CYP) 3A4, organic anion transporter (OAP) P1B1, and P-glycoprotein (P-gp) enzymes and may interact with statins that are metabolized by these enzymes [
         <a href="#rid32">
          32
         </a>
         ]. Additional information on the potential interactions between tacrolimus, statins, and other agents can be found elsewhere in this topic. (See
         <a class="local">
          'Three-way drug-drug interactions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cyclosporine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         is extensively metabolized by hepatic and intestinal CYP3A4, is a substrate and inhibitor of P-gp, and inhibits OAT-P1B1 [
         <a href="#rid32">
          32
         </a>
         ]. Thus,
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">
          lovastatin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9532" href="/z/d/drug information/9532.html" rel="external">
          pitavastatin
         </a>
         should not be used to treat hyperlipidemia in patients taking cyclosporine-based immunosuppression for heart transplantation. Rhabdomyolysis has been reported in cyclosporine-treated patients with atorvastatin, simvastatin, lovastatin, and pitavastatin [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sirolimus
         </strong>
         <strong>
          and
         </strong>
         <strong>
          everolimus
         </strong>
         – Similar to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         and
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         are extensively metabolized by the CYP3A4 pathway. Thus,
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         and
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         are probably safe for use in patients taking an everolimus- or sirolimus-containing regimen [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3949485048">
         <span class="h2">
          Cholestyramine
         </span>
         <span class="headingEndMark">
          —
         </span>
         We avoid use of
         <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">
          cholestyramine
         </a>
         in patients who have undergone heart transplantation. Cholestyramine prevents the absorption of many drugs and is known to decrease serum mycophenolic acid levels [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3532667756">
         <span class="h2">
          Red rice yeast
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who have undergone heart transplantation, we avoid use of red yeast rice. Red yeast rice contains monacolin K, which is the active compound in
         <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">
          lovastatin
         </a>
         and leads to interactions between lovastatin and both the calcineurin inhibitors (eg,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ) and the mammalian target of rapamycin inhibitors (eg,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ). As such, red yeast rice likely interacts with cyclosporine,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         , sirolimus, and
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         , though the data are limited to case reports [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1174383360">
         <span class="h2">
          Three-way drug-drug interactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some drugs may interact with statins and, in turn, with immunosuppressive agents or other components of the patient’s drug regimen. For patients who are posttransplantation and who take a statin and have an indication for one of these medications (or other agent with unclear interactions), we recommend consultation with a transplant pharmacist to determine the risk of the interaction and the need for further monitoring or alternative therapy.
        </p>
        <p>
         In the presence of statin therapy and standard posttransplantation immunosuppression, common drugs that may lead to a three-way drug-drug interaction include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         or
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antifungal agents
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          Colchicine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H193896271">
         <span class="h1">
          THERAPY IN SPECIAL POPULATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         LDL apheresis for patients with familial hypercholesterolemia is rarely used in patients with heart transplantation [
         <a href="#rid36">
          36
         </a>
         ]. While data are limited, LDL apheresis is likely safe in patients who have undergone heart transplantation [
         <a href="#rid37">
          37-39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4554.html" rel="external">
          "Treatment of drug-resistant hypercholesterolemia", section on 'LDL apheresis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3251525242">
         <span class="h1">
          DONOR TREATMENT WITH STATINS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ischemia-reperfusion injury at the time of organ harvest and transplant can result in early adverse events such as primary graft dysfunction (PGD) and later adverse events such as cardiac allograft vasculopathy (CAV) from endothelial injury. Statins have been shown to protect against this injury. A 2019 randomized trial of
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         80 mg versus no statin in 42 donors found a reduction in the surrogate endpoints of biomarkers of myocardial injury after heart transplantation and the number of rejection episodes associated with hemodynamic compromise. No adverse effects were seen [
         <a href="#rid40">
          40
         </a>
         ]. Whether this therapy reduces the incidence or severity of PGD and CAV is not known.
        </p>
        <p class="headingAnchor" id="H2531826256">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109532.html" rel="external">
          "Society guideline links: Lipid disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/3439.html" rel="external">
          "Patient education: Heart transplantation (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4125160196">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes of hyperlipidemia after transplantation
         </strong>
         – After heart transplantation, the risk of hyperlipidemia is increased by factors that include the use of glucocorticoids, calcineurin inhibitors, mechanistic target of rapamycin (mTOR) inhibitors, and others. (See
         <a class="local">
          'Causes of hyperlipidemia after transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of hypercholesterolemia
         </strong>
         – The treatment of patients after transplantation includes the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General measures
         </strong>
         – Patients with hypercholesterolemia posttransplantation should be counseled to engage in activities that may help to reduce hypercholesterolemia, such as diet, exercise, and glycemic control. (See
         <a class="local">
          'General measures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Empiric therapy
         </strong>
         – For all patients who have undergone heart transplantation, regardless of lipid levels or prior treatment with a statin, we recommend initial treatment with
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         or
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         rather than treatment with other cholesterol-reducing agents or no therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ) (
         <a class="graphic graphic_algorithm graphicRef139419" href="/z/d/graphic/139419.html" rel="external">
          algorithm 1
         </a>
         ). We generally prefer pravastatin to rosuvastatin due to the long experience with pravastatin in heart transplantation. (See
         <a class="local">
          'Empiric therapy with a statin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with heart transplantation who are intolerant of statins, we suggest empiric treatment with
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         monotherapy or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Additional therapy based on risk
         </strong>
         – In patients with a heart transplant, we typically treat to achieve low-density lipoprotein-cholesterol (LDL-C) targets that are used for other patients at risk of cardiovascular disease (
         <a class="graphic graphic_algorithm graphicRef139419" href="/z/d/graphic/139419.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Additional therapy based on risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Patients not at goal
         </strong>
         – In patients whose LDL-C is not suppressed below their target values after initial therapy with a statin, we switch to
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         if the patient is not already taking rosuvastatin.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         If the patient has not achieved an LDL-C level consistent with appropriate treatment goals with optimal statin therapy, we suggest treating with the addition of either
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         or a PCSK9 inhibitor rather than no therapy or additional therapy with other agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Patients at goal
         </strong>
         – If the LDL-C is at an appropriate level for the patient’s cardiovascular disease (CVD) risk factor profile, we continue the maximally tolerated statin dose and monitor for liver toxicity and rhabdomyolysis as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of hypertriglyceridemia
         </strong>
         – In patients who already engage in lifestyle modifications and who are maximally treated with
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         but whose triglycerides remain above goal, we typically treat with omega-3 fatty acids; we avoid use of fibrates in this population due to the potential for drug-drug interactions and myotoxicity caused by concomitant renal dysfunction. (See
         <a class="local">
          'Treatment of hypertriglyceridemia'
         </a>
         above and
         <a class="local">
          'Immunosuppression and antihyperlipidemic drug interactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunosuppression and antihyperlipidemic drug interactions
         </strong>
         – Important interactions between immunosuppression and lipid-lowering therapies include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fibrates
         </strong>
         – We do not use fibrates in patients who have undergone heart transplantation due to the potential interactions between immunosuppressants and these agents. (See
         <a class="local">
          'Fibrates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Statins
         </strong>
         – Many of the statins interact with transplant immunosuppressants. The interactions are specific to the statin and immunosuppressant combination. (See
         <a class="local">
          'Statins'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cholestyramine
         </strong>
         <strong>
          and red rice yeast
         </strong>
         –
         <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">
          Cholestyramine
         </a>
         and red rice yeast should not be used in patients who have undergone heart transplantation. (See
         <a class="local">
          'Cholestyramine'
         </a>
         above and
         <a class="local">
          'Red rice yeast'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Three-way drug-drug interactions
         </strong>
         – Some drugs may interact with statins and, in turn, interact with immunosuppressive agents or other components of the patient’s drug regimen. Common drugs that may create a three-way drug-drug interaction include
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ,
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , antifungal agents,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients who are posttransplantation and who take a statin and have an indication for one of these medications (or other agent with unclear interactions), we recommend consultation with a transplant pharmacist to determine the risk of the interaction and the need for further monitoring or alternative therapy. (See
         <a class="local">
          'Three-way drug-drug interactions'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Becker DM, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988; 85:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lake KD, Reutzel TJ, Pritzker MR, et al. The impact of steroid withdrawal on the development of lipid abnormalities and obesity in heart transplant recipients. J Heart Lung Transplant 1993; 12:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renlund DG, Bristow MR, Crandall BG, et al. Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunosuppression. J Heart Transplant 1989; 8:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White M, Haddad H, Leblanc MH, et al. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. J Heart Lung Transplant 2005; 24:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 2013; 13:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markell MS, Friedman EA. Hyperlipidemia after organ transplantation. Am J Med 1989; 87:61N.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992; 19:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker DM, Markakis M, Sension M, et al. Prevalence of hyperlipidemia in heart transplant recipients. Transplantation 1987; 44:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamler JS, Vaughan DE, Loscalzo J. Immunosuppressive therapy and lipoprotein abnormalities after cardiac transplantation. Am J Cardiol 1991; 68:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor DO, Thompson JA, Hastillo A, et al. Hyperlipidemia after clinical heart transplantation. J Heart Transplant 1989; 8:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudas L, Pflugfelder PW, McKenzie FN, et al. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol 1990; 66:1135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96:1398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng TO. Determinants of post-cardiac transplantation hypercholesterolemia. Am J Cardiol 1993; 71:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehra MR, Uber PA, Vivekananthan K, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002; 40:1609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oswald S, Nassif A, Modess C, et al. Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther 2010; 87:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oswald S, Nassif A, Modess C, et al. Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther 2011; 89:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crespo-Leiro MG, Paniagua MJ, Marzoa R, et al. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation. Transplant Proc 2008; 40:3060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moro J, Almenar L, Martínez-Dolz L, et al. Ezetimibe in heart transplantation: initial experience. Transplant Proc 2007; 39:2389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moayedi Y, Kozuszko S, Knowles JW, et al. Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation. Can J Cardiol 2019; 35:104.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jennings DL, Sultan L, Mingov J, et al. PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis. Heart Fail Rev 2023; 28:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sammour Y, Dezorzi C, Austin BA, et al. PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates. J Card Fail 2021; 27:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celik S, Doesch A, Erbel C, et al. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation 2008; 86:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pisanti N, Stanziale P, Imperatore P, et al. Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients. Am J Nephrol 1998; 18:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fehrman-Ekholm I, Jogestrand T, Angelin B. Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation. Nephron 1996; 72:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Migliozzi DR, Asal NJ. Clinical Controversy in Transplantation: Tacrolimus Versus Cyclosporine in Statin Drug Interactions. Ann Pharmacother 2020; 54:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemahieu WP, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005; 5:2236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amundsen R, Christensen H, Zabihyan B, Asberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos 2010; 38:1499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2016; 134:e468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Page RL 2nd, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation 2005; 111:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002; 74:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valdivielso P, Escolar JL, Cuervas-Mons V, et al. Lipids and lipoprotein changes after heart and liver transplantation in a patient with homozygous familial hypercholesterolemia. Ann Intern Med 1988; 108:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaeger BR, Schirmer J, Thiery J, et al. Coronary risk factor management for the prevention and treatment of graft vessel disease in heart transplant patients. Ther Apher 1999; 3:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JW, Merz M, Braun P. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J Heart Lung Transplant 1997; 16:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilchick KC, Henrikson CA, Skojec D, et al. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 2004; 148:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nykänen AI, Holmström EJ, Tuuminen R, et al. Donor Simvastatin Treatment in Heart Transplantation. Circulation 2019; 140:627.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3521 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3055976" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8369320" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The impact of steroid withdrawal on the development of lipid abnormalities and obesity in heart transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2661771" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15982605" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12944570" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23433101" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18510633" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2486550" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Hyperlipidemia after organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1564233" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3307054" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prevalence of hyperlipidemia in heart transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1858681" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Immunosuppressive therapy and lipoprotein abnormalities after cardiac transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2661770" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hyperlipidemia after clinical heart transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2220642" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7637722" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Effect of pravastatin on outcomes after cardiac transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9315523" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8438763" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Determinants of post-cardiac transplantation hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20643330" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12427413" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20220747" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21368751" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19010194" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17889199" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Ezetimibe in heart transplantation: initial experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30595172" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35687219" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33753241" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18645486" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9627035" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8852502" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31441337" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical Controversy in Transplantation: Tacrolimus Versus Cyclosporine in Statin Drug Interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16095503" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20519340" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27754879" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12622602" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Risk for myopathy with statin therapy in high-risk patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15657387" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Drug therapy in the heart transplant recipient: part IV: drug-drug interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12438974" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3277507" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Lipids and lipoprotein changes after heart and liver transplantation in a patient with homozygous familial hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10427618" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Coronary risk factor management for the prevention and treatment of graft vessel disease in heart transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9087872" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15308989" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Treatment of hyperlipidemia in cardiac transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31352795" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Donor Simvastatin Treatment in Heart Transplantation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
